Follow
Akshay Jain
Title
Cited by
Cited by
Year
The principles and applications of avidin-based nanoparticles in drug delivery and diagnosis
A Jain, K Cheng
Journal of controlled release 245, 27-40, 2017
2512017
Enzyme-responsive polymeric micelles of cabazitaxel for prostate cancer targeted therapy
A Barve, A Jain, H Liu, Z Zhao, K Cheng
Acta biomaterialia 113, 501-511, 2020
1032020
Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
H Liu, Z Zhao, L Zhang, Y Li, A Jain, A Barve, W Jin, Y Liu, J Fetse, ...
Journal for immunotherapy of cancer 7, 1-14, 2019
892019
Comparison of avidin, neutravidin, and streptavidin as nanocarriers for efficient siRNA delivery
A Jain, A Barve, Z Zhao, W Jin, K Cheng
Molecular pharmaceutics 14 (5), 1517-1527, 2017
802017
Targeted drug delivery to hepatic stellate cells for the treatment of liver fibrosis
Z Chen, A Jain, H Liu, Z Zhao, K Cheng
Journal of Pharmacology and Experimental Therapeutics 370 (3), 695-702, 2019
782019
Intracellular trafficking and exocytosis of a multi-component siRNA nanocomplex
RS Shukla, A Jain, Z Zhao, K Cheng
Nanomedicine: Nanotechnology, Biology and Medicine 12 (5), 1323-1334, 2016
622016
Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer
Z Zhao, Y Li, H Liu, A Jain, PV Patel, K Cheng
Science advances 6 (29), eabb0616, 2020
572020
Development of a peptide-modified siRNA nanocomplex for hepatic stellate cells
Z Zhao, Y Li, A Jain, Z Chen, H Liu, W Jin, K Cheng
Nanomedicine: Nanotechnology, Biology and Medicine 14 (1), 51-61, 2018
512018
Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer
Z Zhao, Y Li, R Shukla, H Liu, A Jain, A Barve, K Cheng
Theranostics 9 (15), 4508-4524, 2019
442019
Discovery of Aptamer Ligands for Hepatic Stellate Cells Using SELEX
Z Chen, H Liu, A Jain, L Zhang, C Liu, K Cheng
Theranostics 7 (12), 2982-2995, 2017
372017
Development of a tumor-responsive nanopolyplex targeting pancreatic cancer cells and stroma
Y Li, Z Zhao, H Liu, JP Fetse, A Jain, CY Lin, K Cheng
ACS applied materials & interfaces 11 (49), 45390-45403, 2019
342019
An enzyme-responsive conjugate improves the delivery of a PI3K inhibitor to prostate cancer
A Barve, A Jain, H Liu, W Jin, K Cheng
Nanomedicine: Nanotechnology, Biology and Medicine 12 (8), 2373-2381, 2016
322016
Targeted Delivery of an siRNA/PNA Hybrid Nanocomplex Reverses Carbon Tetrachloride‐Induced Liver Fibrosis
A Jain, A Barve, Z Zhao, JP Fetse, H Liu, Y Li, K Cheng
Advanced Therapeutics 2 (8), 1900046, 2019
222019
Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists
A Zacharia, E Harberts, SM Valencia, B Myers, C Sanders, A Jain, ...
Vaccine 39 (2), 292-302, 2021
172021
Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery
P Patel, J Fetse, CY Lin, Y Guo, MR Hasan, M Nakhjiri, Z Zhao, A Jain, ...
Acta biomaterialia 154, 374-384, 2022
92022
Discovery of Anti-PD-L1 Human Domain Antibodies for Cancer Immunotherapy
H Liu, Y Liu, Z Zhao, Y Li, B Mustafa, Z Chen, A Barve, A Jain, X Yao, G Li, ...
Frontiers in Immunology, 1345, 2022
72022
Noncovalent Attachment of Chemical Moieties to siRNAs Using Peptide Nucleic Acid as a Complementary Linker
W Jin, A Jain, H Liu, Z Zhao, K Cheng
ACS applied bio materials 1 (3), 643-651, 2018
42018
Subunit-based vaccines: challenges in developing protein-based vaccines
SF Ausar, NR Larson, Y Wei, A Jain, CR Middaugh
Practical Aspects of Vaccine Development, 79-135, 2022
22022
Preformulation characterization and the effect of ionic excipients on the stability of a novel DB fusion protein
A Jain, G Hu, SSK Ratnakaram, DK Johnson, WD Picking, WL Picking, ...
Journal of pharmaceutical sciences 110 (1), 108-123, 2021
22021
Impact of the TLR4 agonist BECC438 on a novel vaccine formulation against Shigella spp.
T Lu, S Das, DR Howlader, A Jain, G Hu, ZK Dietz, Q Zheng, ...
Frontiers in Immunology 14, 1194912, 2023
12023
The system can't perform the operation now. Try again later.
Articles 1–20